Clinical trials: Antiplatelet Effect
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
CORONARY ARTERY DISEASE
"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"
Prasugrel is a potent thienopyridine antiplatelet agent that selectively and irreversibly inhibits ADP-induced platelet aggregation mediated by the P2Y12 receptor.
- Trial name
- CyCLOPS (NCT02054988)
- Testing
- caffeine, not caffeine
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Healthy
The Antiplatelet and Immune Response Trial
Platelets are the main type of blood cell involved in the formation of blood clots that cause heart attacks. The investigators give antiplatelet drugs (aspirin, for example) to reduce the risk of another clot forming in the…
- Trial name
- NCT01846559
- Testing
- Endotoxin, Clopidogrel, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Antiplatelet Effect
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans.
- Trial name
- NCT00688714
- Testing
- AZD6482
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dietary Exposure
Effect of Tomato Soffritto Intake on Biomarkers of Cardiovascular Disease in an Overweight and Obesity
The study is a prospective, controlled, randomized two-arm longitudinal crossover trial, performed in a single-centre. Hence, the investigators designed a clinical study aimed to investigate the effects of a daily intake of…
- Trial name
- FRITOCARD (NCT06161883)
- Testing
- Soffritto
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cardiovascular Diseases
In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid
This is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite (AR-C124910XX) and their effects on the pharmacodynamics of salicylic acid.
- Trial name
- In_vitro_PAT (NCT01777516)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Myocardial Infarction
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors are essential for platelet activation.
- Trial name
- AFFECT EV (NCT02931045)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Platelet Function and Reactivity Tests
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
- Trial name
- NCT06933056
- Testing
- Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Florida
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Antiplatelet Effect
Bleeding Time Study With AZD6482, Clopidogrel and ASA
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
- Trial name
- NCT00853450
- Testing
- AZD6482, Clopidogrel, ASA
- Where
- Sweden
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ticagrelor, Aspirin
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.
- Conditions
- Ticagrelor, Aspirin, Platelet Dysfunction Due to Drugs, Transfusion
- Trial name
- REVSTARTS (NCT03005704)
- Testing
- Antiplatelet treatment
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Healthy Volunteers
Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action
This study in healthy volunteers is the first step in developing a collaborative research program, which seeks to test the hypothesis that chemopreventive effect of acetylsalicylic acid (ASA) on colon cancer is due predominantly…
- Trial name
- NCT02060396
- Testing
- Acetylsalicylic acid
- Where
- Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Aragon Institute of Health Sciences
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Healthy
The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers
Background: The prevalence of arthritis which needs celecoxib prescription is high in patients with coronary artery disease. The main concern is that celecoxib would increase thrombogenicity by inhibiting the synthesis of…
- Trial name
- NCT00882388
- Testing
- aspirin, celecoxib, aspirin + celecoxib
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese
This study is a open and single center clinical trial in healthy Chinese.The objective of the study is to clarify the pharmacokinetics characteristics and antiplatelet effects of ticagrelor in Chinese and to investigate the…
- Trial name
- IGPPT (NCT03092076)
- Testing
- Ticagrelor
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital